Advertisement

Search Results

Advertisement



Your search for Matthew Stenger matches 557 pages

Showing 1 - 50


breast cancer

Addition of Radiotherapy After Breast-Conserving Surgery Based on Level of Tumor-Infiltrating Lymphocytes

In a long-term follow-up of the Swedish Breast Cancer Group 91 Radiotherapy trial reported in the Journal of Clinical Oncology, Kovács et al found that higher levels of stromal tumor–infiltrating lymphocytes (TILs) and receipt of radiotherapy were independently associated with reduced...

breast cancer

Follow-up of Adjuvant Paclitaxel and Trastuzumab in Small HER2-Positive Breast Tumors

As reported in the Journal of Clinical Oncology by Tolaney et al, 7-year follow-up of the phase II Adjuvant Paclitaxel and Trastuzumab trial showed that adjuvant paclitaxel and trastuzumab were associated with “excellent” outcomes in women with small, node-negative HER2-positive breast...

breast cancer
gynecologic cancers

Actionable Pathogenic Variants in a Population-Based Cohort of Patients With Breast or Ovarian Cancer

In a study reported in the Journal of Clinical Oncology, Kurian et al found that approximately one-quarter of women with breast cancer and one-third of those with ovarian cancer underwent cancer genetic testing, and that 8% to 15% of those tested had actionable pathogenic variants. Study Details...

breast cancer
issues in oncology

Effect of Exercise Intervention on Cardiovascular Disease Risk in Overweight or Obese Patients With Early-Stage Breast Cancer

In a study reported in JAMA Oncology, Lee et al found that an aerobic and resistance exercise intervention reduced Framingham Risk Scores (FRS) for cardiovascular disease among overweight or obese women with early-stage breast cancer. In the single-center trial, 100 women with stage I to III...

breast cancer

Stromal Tumor–Infiltrating Lymphocytes and Outcomes in Early-Stage HER2-Positive Breast Cancer

In a study reported in the Journal of the National Cancer Institute, Kim and colleagues found that higher levels of stromal tumor–infiltrating lymphocytes (TILs) were associated with better outcomes in patients receiving adjuvant chemotherapy or trastuzumab plus chemotherapy for early-stage...

breast cancer

Final Overall Survival Results With Fulvestrant Plus Anastrozole in Metastatic Breast Cancer

As reported in The New England Journal of Medicine by Mehta et al, the final overall survival results of the phase III SWOG S0226 trial show that the addition of first-line fulvestrant to anastrozole was associated with improved overall survival in postmenopausal women with hormone...

breast cancer
survivorship

Patient Preferences for Oncologist and Primary Care Provider Roles After Initial Breast Cancer Treatment

In a study reported in the Journal of Oncology Practice, Radhakrishnan et al found that the level of involvement of medical oncologists and primary care physicians during initial cancer care in women with early-stage breast cancer affected patients’ preference for provider roles after initial ...

breast cancer

Artificial Intelligence vs Radiologists in Breast Cancer Detection With Digital Mammography

In a study reported in the Journal of the National Cancer Institute, Rodriguez-Ruiz et al found that a stand-alone artificial intelligence (AI) system had accuracy comparable to an average breast radiologist in detecting breast cancer using digital mammography. Study Details In the retrospective...

breast cancer

Validation Study of Several Models of Breast Cancer Risk

In a validation study reported in The Lancet Oncology, Terry et al found that the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm model (BOADICEA) and the International Breast Cancer Intervention Study model (IBIS) were the best of 4 models tested for predicting...

breast cancer

Neratinib Plus Capecitabine Active Against HER2-Positive Breast Cancer Brain Metastases

In the phase II TBCRC 022 trial reported in the Journal of Clinical Oncology, Freedman et al found that the combination of neratinib and capecitabine was active against brain metastases in women with HER2-positive breast cancer. Modest activity of neratinib monotherapy had been found in previous...

breast cancer
colorectal cancer
lung cancer
pain management

Opioid Use Among Older Survivors of Colorectal, Lung, and Breast Cancers

In a linked Surveillance, Epidemiology, and End Results and Medicare study reported in the Journal of Clinical Oncology, Salz et al found that chronic opioid use varied by cancer among older cancer survivors. By 6 years after diagnosis, survivors were no more likely to be chronic opioid users...

breast cancer

Use of Specialized PET/CT to Assess Estrogen Receptor Status in Recurrent or Metastatic Breast Cancer

In a Korean study reported in The Lancet Oncology, Chae et al found that 16α-[18F]fluoro-17β-oestradiol (18F-FES) positron-emission tomography/computed tomography (PET/CT) may permit accurate reevaluation of estrogen receptor status in recurrent or metastatic breast cancer when repeat...

breast cancer

Addition of Preoperative Breast MRI to Standard Evaluation in Local Ductal Carcinoma in Situ

In a French phase III trial reported in the Journal of Clinical Oncology, Balleyguier et al found that the addition of breast magnetic resonance imaging (MRI) to standard radiologic evaluation did not improve surgical reintervention rates in women with ductal carcinoma in situ undergoing...

breast cancer
solid tumors
gynecologic cancers
lymphoma
survivorship

Subsequent Primary Neoplasms in Survivors of Adolescent and Young Adult Cancers

In a UK population-based cohort study (Teenage and Young Adult Cancer Survivor Study) reported in The Lancet Oncology, Bright et al found that subsequent primary neoplasms were most common in survivors of adolescent and young adult (AYA) breast, cervical, and testicular cancers, as well as Hodgkin...

breast cancer
survivorship
symptom management

Can Cognitive Behavioral Therapy Improve Treatment-Induced Menopausal Symptoms in Survivors of Breast Cancer?

In a Dutch study reported in the Journal of Clinical Oncology, Atema et al found that an Internet-based cognitive behavioral therapy (iCBT) intervention improved treatment-induced menopausal symptoms in breast cancer survivors compared with a waiting list control group. In the study, 254 women...

breast cancer

Sacituzumab Govitecan-hziy in Heavily Pretreated, Metastatic Triple-Negative Breast Cancer

In a phase I/II trial reported in The New England Journal of Medicine, Bardia et al found durable responses with the antibody-drug conjugate sacituzumab govitecan-hziy in patients with heavily pretreated, metastatic triple-negative breast cancer. The monoclonal antibody sacituzumab targets the...

breast cancer
immunotherapy

Addition of Pembrolizumab to Trastuzumab in PD-L1–Positive, Trastuzumab-Resistant, HER2-Positive Breast Cancer

In the phase II portion of a phase Ib/II trial reported in The Lancet Oncology, Loi et al found evidence of activity of pembrolizumab plus trastuzumab in programmed cell death protein ligand 1 (PD-L1)-positive, trastuzumab-resistant, HER2-positive advanced breast cancer. Study Details In the...

breast cancer

Meta-analysis of Outcomes With Dose-Intense Adjuvant Chemotherapy in Early Breast Cancer

In a patient-level meta-analysis reported in The Lancet, the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) found that an increased dose intensity of adjuvant taxane and anthracycline chemotherapy in early breast cancer was associated with a decreased risk of recurrence and death ...

breast cancer

New Approach to Predicting Response to Pertuzumab and Trastuzumab in Breast Cancer

In the phase II TBCRC026 study reported in the Journal of Clinical Oncology, Connolly et al found that early changes in tumor maximum standardized uptake values corrected for lean body mass (SULmax) on [18F]fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) were...

breast cancer

MRI and Assay Results May Influence Treatment of DCIS

In a prospective cohort clinical trial reported in JAMA Oncology, Lehman et al found that multiple factors, including magnetic resonance imaging (MRI) findings, played a role in conversion to mastectomy among women with ductal carcinoma in situ (DCIS) who were candidates for wide local excision...

breast cancer

Postmastectomy Hypofractionated vs Conventionally Fractionated Radiotherapy for High-Risk Breast Cancer

In a Chinese, single-center, noninferiority phase III trial reported in The Lancet Oncology, Wang et al found that postmastectomy hypofractionated radiotherapy was noninferior to and associated with similar toxicities vs conventionally fractionated radiotherapy in patients with high-risk breast...

breast cancer

CYP2D6 Genotypes, Endoxifen Levels, and Clinical Outcome in Early-Stage Breast Cancer Treated With Adjuvant Tamoxifen

In a Dutch-Belgian study (CYPTAM) reported in the Journal of Clinical Oncology, Sanchez-Spitman et al found no associations between CYP2D6 genotypes or levels of endoxifen (active metabolite of tamoxifen) and clinical outcomes in patients receiving adjuvant tamoxifen for early-stage breast cancer....

breast cancer

Effect of Peer Review Within a Cancer Care Network on Use of Hypofractionated Radiotherapy for Early-Stage Breast Cancer

In a study reported in the Journal of Oncology Practice, Ganju et al found that implementation of a cancer care network–wide peer review process aimed at standardizing treatment resulted in increasing use of hypofractionated radiotherapy in early-stage breast cancer at community-based...

breast cancer
issues in oncology

Racial Differences in Time to Breast Cancer Surgery and Survival in the U.S. Military Health System

In a retrospective cohort study reported in JAMA Surgery, Eaglehouse et al found that time to breast cancer surgery was delayed for non-Hispanic black vs non-Hispanic white women in the Military Health System but that this difference did not account for poorer overall survival in non-Hispanic black ...

breast cancer

Short-Term Safety Outcomes in Mastectomy and Immediate Implant-Based Breast Reconstruction

In a prospective cohort study reported in The Lancet Oncology, Potter et al found that complications following immediate implant-based breast reconstruction—with or without mesh—were higher than considered acceptable by UK national standards. As noted by the investigators, the study was ...

breast cancer

Tumor-Infiltrating Lymphocytes and Prognosis in Early-Stage Triple-Negative Breast Cancer

In a pooled analysis reported in the Journal of Clinical Oncology, Loi et al found that levels of stromally located tumor infiltrating lymphocytes (sTILs) are strongly prognostic in early-stage triple-negative breast cancer, with improved survival observed in patients with higher levels of sTILs...

breast cancer

MRI Background Parenchymal Enhancement and Risk of Breast Cancer

In a population-based study reported in the Journal of Clinical Oncology, Arasu and colleagues found that increased breast magnetic resonance imaging (MRI) background parenchymal enhancement was associated with an increased risk of breast cancer, with risk being independent of breast density. The...

breast cancer

Breast Cancer Surveillance Consortium Analysis of Trends in Breast Density Assessment

In a study reported in the Journal of the National Cancer Institute, Sprague et al found that only small changes in the proportions of women found to have dense breasts on digital mammography have occurred with revisions in Breast Imaging Reporting and Data System (BI-RADS) density classification...

breast cancer

Neoadjuvant Degarelix vs Triptorelin in Premenopausal Women Receiving Letrozole for Locally Advanced, Endocrine-Responsive Breast Cancer

In a phase II trial reported in the Journal of Clinical Oncology, Dellapasqua et al found that neoadjuvant treatment with the gonadotropin-releasing hormone (GnRH) antagonist degarelix was more effective than the GnRH agonist triptorelin in achieving ovarian function suppression (OFS) in...

breast cancer

Adjuvant Trastuzumab Emtansine vs Trastuzumab in Patients With HER2-Positive Breast Cancer With Residual Disease After Neoadjuvant Therapy

As reported at the recent San Antonio Breast Cancer Symposium and in The New England Journal of Medicine by von Minckwitz et al, an interim analysis of the phase III KATHERINE trial has shown that adjuvant trastuzumab emtansine (T-DM1; Kadcyla) improved invasive disease–free survival vs...

breast cancer

Disease-Free Survival With Letrozole vs Placebo After Aromatase Inhibitor–Based Therapy in Postmenopausal Breast Cancer

As reported by Mamounas et al in The Lancet Oncology, the phase III NRG Oncology/NSABP B-42 trial has shown no disease-free survival benefit with 5 years of letrozole (Femara) vs placebo after 5 years of aromatase inhibitor–based therapy in women with hormone receptor–positive...

breast cancer

Addition of Neoadjuvant Palbociclib to Letrozole in Estrogen Receptor–Positive Early Breast Cancer

In the phase II PALLET trial reported in the Journal of Clinical Oncology, Johnston et al found that the addition of neoadjuvant palbociclib (Ibrance) to letrozole increased rates of complete cell-cycle arrest, reduced apoptosis, and did not significantly improve clinical response rate in patients...

breast cancer

Palbociclib Plus Fulvestrant in Advanced Breast Cancer: Overall Survival Analysis of PALOMA-3

An overall survival analysis of the PALOMA-3 trial reported by Turner et al in The New England Journal of Medicine found that the addition of the cyclin-dependent kinase 4/6 (CDK4/6) inhibitor palbociclib (Ibrance) to fulvestrant (Faslodex) improved survival among patients with hormone...

breast cancer
survivorship

POEMS/SWOG Intergroup S0230 Study on Preventing Early Menopause

In the long-term follow-up of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230 trial reported in the Journal of the National Cancer Institute, Moore et al found that the addition of goserelin (Zoladex) to cyclophosphamide-containing chemotherapy was associated with a higher...

breast cancer
issues in oncology

Discontinuation of Follow-up Care Among Women With Early-Stage Breast Cancer

In a study using linked Surveillance, Epidemiology, and End Results (SEER)-Medicare data reported in the Journal of Oncology Practice, Quyyumi et al found that 21% of women with early-stage breast cancer discontinued follow-up care within 5 years after diagnosis. Study Details The study involved...

breast cancer
issues in oncology
survivorship

Adverse Mental Health Outcomes in Breast Cancer Survivors

In a systematic review of the literature reported in the Journal of the National Cancer Institute, Carreira et al found that most evidence strongly supports increased risk of anxiety, depression, neurocognitive dysfunction, and other forms of psychological issues in survivors of breast...

breast cancer

Neoadjuvant Chemotherapy With vs Without Anthracyclines Plus Dual HER2 Inhibitors in HER2-Positive Breast Cancer

In the Dutch Breast Cancer Research Group’s phase III TRAIN-2 trial reported in The Lancet Oncology, van Ramshorst et al found no difference in pathologic complete response rate with neoadjuvant chemotherapy with vs without an anthracycline plus dual HER2 blockade in women with HER2-positive...

breast cancer

Patient-Reported Cosmetic Outcomes With Radiotherapy in Early Breast Cancer

As reported in the Journal of Clinical Oncology by Shaitelman et al, 3-year outcomes of a phase III noninferiority trial indicate that hypofractionated whole-breast irradiation (HF-WBI) followed by a tumor bed boost is not inferior to conventionally fractionated whole-breast irradiation (CF-WBI)...

breast cancer

Quality of Life With Postmastectomy Radiotherapy vs No Radiotherapy in Intermediate-Risk Breast Cancer

In a 2-year follow-up of the phase III SUPREMO trial reported in The Lancet Oncology, Velikova et al found worse chest wall symptoms in women with intermediate-risk breast cancer who did vs did not receive postmastectomy radiotherapy. No other differences in quality-of-life outcomes were found ...

breast cancer
issues in oncology

Adherence to Endocrine Therapy for Breast Cancer in Black Women and White Women

In a study reported in the Journal of the National Cancer Institute, Wheeler et al found that black women reported nonadherence to endocrine therapy for breast cancer more often than white women, although no significant difference in discontinuation of treatment was observed. The study...

breast cancer
issues in oncology
survivorship

Cognitive Outcomes Among Older Survivors of Breast Cancer

In a study (Thinking and Living with Cancer) reported in the Journal of Clinical Oncology, Mandelblatt et al found that poorer cognitive function in older survivors of breast cancer was associated with chemotherapy, hormone therapy, and ApoE genotype. The ApoE ε4 allele has been associated...

breast cancer
issues in oncology

Cognitive Impairment in Patients With Breast Cancer Treated With Chemotherapy

In a study reported in the Journal of Clinical Oncology, Janelsins et al found cognitive impairment in women receiving chemotherapy for breast cancer that persisted for at least 6 months after treatment. Study Details The study, conducted within the National Cancer Institute Community Clinical...

breast cancer

Lurbinectedin in BRCA-Mutated and Unselected Metastatic Breast Cancer

In a phase II study reported in the Journal of Clinical Oncology, Cruz et al found that the trabectedin (Yondelis) analog lurbinectedin was active in patients with metastatic breast cancer with germline BRCA mutations, with much lower activity in those without BRCA mutation or unknown mutation...

breast cancer

Neoadjuvant Paclitaxel With LCL161 in Localized Triple-Negative Breast Cancer

In a phase II study reported in the Journal of Clinical Oncology, Bardia et al evaluated the effects of adding an antagonist of inhibitor of apoptosis proteins (LCL161) to paclitaxel as neoadjuvant therapy in patients with localized triple-negative breast cancer who did or did not have a tumor...

breast cancer
immunotherapy

Long-Term Outcomes With Anti–PD-L1 Treatment in Metastatic Triple-Negative Breast Cancer

In a long-term follow-up of a phase I trial reported in JAMA Oncology, Emens et al found that single-agent atezolizumab (Tecentriq) produced enduring benefit in patients with metastatic triple-negative breast cancer after stable or responding disease and in first-line treatment. Study Details In...

breast cancer

NCI Breast Cancer Working Group Report on Appropriate Endpoints for Clinical Trials in Metastatic Breast Cancer

As reported in the Journal of Clinical Oncology by Seidman et al, the National Cancer Institute (NCI) Breast Cancer Steering Committee Working Group has issued a report on meaningful and appropriate endpoints for clinical trials in metastatic breast cancer. With the goal of providing...

breast cancer

Breast Pathologic Complete Response and Pathologic Node Positivity After Neoadjuvant Therapy

In a National Cancer Database analysis reported in JAMA Surgery, Barron et al found low pathologic nodal positivity rates among patients with clinically node-negative (cN0), HER2-positive disease or triple-negative breast cancer with breast pathologic complete response (pCR) after neoadjuvant...

breast cancer
immunotherapy

Sequential vs Concurrent Neoadjuvant Therapy in HER2-Positive Breast Cancer

As reported in JAMA Oncology by Buzdar et al, the phase III ACOSOG Z1041 (Alliance) trial showed no difference in disease-free or overall survival with sequential vs concurrent neoadjuvant anthracycline and trastuzumab in patients with operable HER2-positive breast cancer. An earlier report from...

breast cancer

Danish Study on Effect of Screening on Breast Cancer Mortality

In a Danish study reported in the Journal of Clinical Oncology, Beau et al used different models to assess the effects of screening on breast cancer mortality, finding a 20% reduction among patients diagnosed during the recommended screening age range. As noted by the investigators, the study was...

breast cancer

10-Year Follow-up of Axillary Dissection vs No Dissection in Breast Cancer With Sentinel Node Micrometastases

In the 10-year follow-up of the phase III International Breast Cancer Study Group (IBCSG) 23-01 trial reported in The Lancet Oncology, Galimberti et al found no significant difference in disease-free survival with axillary dissection vs no axillary dissection in patients with breast cancer and...

Advertisement

Advertisement



;
Advertisement